R Coleman Lindsley
Overview
Explore the profile of R Coleman Lindsley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
6690
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gurnari C, Robin M, Ades L, Aljurf M, Almeida A, Duarte F, et al.
Blood
. 2025 Feb;
PMID: 39970324
For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis. Biologic-assignment...
2.
Schneider R, Schenone M, Ferreira M, Kramann R, Joyce C, Hartigan C, et al.
Nat Med
. 2024 Oct;
30(11):3382.
PMID: 39443719
No abstract available.
3.
Venkat R, Redd R, Harris A, Aryee M, Marneth A, Kamaz B, et al.
Blood Adv
. 2024 Sep;
8(23):6043-6054.
PMID: 39293089
Approximately 25% of patients with essential thrombocythemia (ET) present with extreme thrombocytosis (ExT), defined as having a platelet count ≥1000 × 109/L. ExT patients may have an increased bleeding risk...
4.
Jann J, Hergott C, Winkler M, Liu Y, Braun B, Charles A, et al.
Leukemia
. 2024 Jul;
38(9):1992-2002.
PMID: 39033241
Mutations in the cohesin complex components (STAG2, RAD21, SMC1A, SMC3, and PDS5B) are recurrent genetic drivers in myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML). Whether the different cohesin subunit...
5.
Vedula R, Karp H, Koob J, Lim F, Garcia J, Winer E, et al.
Blood
. 2024 Jul;
144(12):1290-1299.
PMID: 38976877
Fusion oncogenes can be cancer-defining molecular alterations that are essential for diagnosis and therapy selection.1,2 Rapid and accessible molecular diagnostics for fusion-driven leukemias such as acute promyelocytic leukemia (APL), Philadelphia...
6.
Bewersdorf J, Shimony S, Shallis R, Liu Y, Berton G, Schaefer E, et al.
Blood Adv
. 2024 Jun;
8(18):4845-4855.
PMID: 38941537
Although intensive induction chemotherapy (IC) remains the standard of care for younger patients with acute myeloid leukemia (AML), hypomethylating agents + venetoclax (HMA/VEN) can lead to durable remission among older...
7.
Bewersdorf J, Shimony S, Shallis R, Liu Y, Berton G, Schaefer E, et al.
Am J Hematol
. 2024 May;
99(8):1640-1643.
PMID: 38751104
No abstract available.
8.
Shimony S, Garcia J, Keating J, Chen E, Luskin M, Stahl M, et al.
Leukemia
. 2024 Mar;
38(7):1494-1500.
PMID: 38538860
The clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML patients, we evaluated...
9.
Gibson C, Lindsley R, Gondek L
Semin Hematol
. 2024 Mar;
61(1):9-15.
PMID: 38429201
Clonal hematopoiesis (CH) in autologous transplant recipients and allogeneic transplant donors has genetic features and clinical associations that are distinct from each other and from non-cancer populations. CH in the...
10.
Shimony S, Bewersdorf J, Shallis R, Liu Y, Schaefer E, Zeidan A, et al.
Leukemia
. 2024 Feb;
38(4):762-768.
PMID: 38378841
Molecularly defined secondary acute myeloid leukemia is associated with a prior myeloid neoplasm and confers a worse prognosis. We compared outcomes of molecularly defined secondary AML patients (n = 395)...